Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease

Parkinson's Disease

Volumn , Issue , 2012, Pages

  Guridi, J ^a   Gonzalez Redondo R ^a   Obeso, J A ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; AMANTADINE; APOMORPHINE; ARIPIPRAZOLE; BUSPIRONE; CABERGOLINE; CARBIDOPA PLUS LEVODOPA; CLOZAPINE; DEXTROMETHORPHAN; DOPAMINE; FLUOXETINE; HALOPERIDOL; LEVODOPA; MEMANTINE; MIRTAZAPINE; OLANZAPINE; OPIATE ANTAGONIST; PLACEBO; PRAMIPEXOLE; PRECLAMOL; QUETIAPINE; QUINPIROLE; RESERPINE; ROPINIROLE; ROTIGOTINE; SELEGILINE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; UNINDEXED DRUG;

BASAL GANGLION; BRAIN DEPTH STIMULATION; CELL TRANSPLANTATION; CHOREA; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE CONTROL; DOPAMINERGIC ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DYSKINESIA; DYSTONIA; EXCITATION AND STIMULATION; EXCITOTOXICITY; FETAL CELL TRANSPLANT; FOLLOW UP; GLOBUS PALLIDUS INTERNUS; HAPLORHINI; HEMICHOREA BALLISM; HUMAN; LEVODOPA INDUCED DYSKINESIA; LONG TERM CARE; MITRAL VALVE DISEASE; MONOTHERAPY; MOTOR DYSFUNCTION; NONHUMAN; PALLIDOTOMY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; STEREOTAXIC SURGERY; SUBTHALAMIC NUCLEUS; SUBTHALAMOTOMY; TARDIVE DYSKINESIA; THALAMOTOMY; TIC; VIM DEEP BRAIN STIMULATION; VIM THALAMOTOMY; VISUAL ANALOG SCALE;

EID: 84869025446     PISSN: None     EISSN: 20420080     Source Type: Journal    
DOI: 10.1155/2012/943159     Document Type: Review

References (176)

1. Barbeau A., Long term assessment of levodopa therapy in Parkinson's disease. Canadian Medical Association Journal 1975 112 12 1379 1380 2-s2.0-0016858783
2. Marsden C. D., Parkes J. D., Success and problems of long term levodopa therapy in Parkinson's disease. The Lancet 1977 1 8007 345 349 2-s2.0-0017344150 (Pubitemid 8024416)
3. Obeso J. A., Grandas F., Vaamonde J., Luquin M. R., Artieda J., Lera G., Rodriguez M. E., Martinez-Lage J. M., Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology 1989 39 11 supplement 2 11 19 2-s2.0-0024852627 (Pubitemid 20020576)
4. Luquin M. R., Scipioni O., Vaamonde J., Gershanik O., Obeso J. A., Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Movement Disorders 1992 7 2 117 124 2-s2.0-0026551551
5. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E., A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. The New England Journal of Medicine 2000 342 20 1484 1491 2-s2.0-0034682308 10.1056/NEJM200005183422004 (Pubitemid 30318272)
6. Obeso J. A., Rodriguez-Oroz M. C., Rodriguez M., DeLong M. R., Olanow C. W., Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Annals of Neurology 2000 47 4 S22 S34 2-s2.0-0034109592 (Pubitemid 30192007)
7. Růžička E., Zárubová K., Nutt J. G., Bloem B. R., 'Silly Walks' in Parkinson's disease: unusual presentation of dopaminergic-induced dyskinesias. Movement Disorders 2011 26 9 1783 1784 2-s2.0-79961210230 10.1002/mds.23667
8. Freed C. R., Greene P. E., Breeze R. E., Transplantation of embryonic dopamine neurons for severe Parkinson's disease. The New England Journal of Medicine 2001 344 10 710 719 2-s2.0-0035850021 10.1056/NEJM200103083441002 (Pubitemid 32204988)
9. Limousin P., Krack P., Pollak P., Electrical stimulatiion of the subthalamic nucleus in advanced Parekinson's disease. The New England Journal of Medicine 1998 339 16 1105 1111 (Pubitemid 28465758)
10. Olanow C. W., Kordower J. H., Lang A. E., Obeso J. A., Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Annals of Neurology 2009 66 5 591 596 2-s2.0-72949111183 10.1002/ana.21778
11. Olanow C. W., Gracies J. M., Goetz C. G., Stoessl A. J., Freeman T., Kordower J. H., Godbold J., Obeso J. A., Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: a double blind video-based analysis. Movement Disorders 2009 24 3 336 343 2-s2.0-67349088356 10.1002/mds.22208
12. Olanow C. W., Schapira A. H. V., Rascol O., Continuous dopamine-receptor stimulation in early Parkinson's disease. Trends in Neurosciences 2000 23 supplement 10 S117 S126 2-s2.0-0033695789
13. Cenci M. A., Lee C. S., Björklund A., L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. European Journal of Neuroscience 1998 10 8 2694 2706 2-s2.0-0031925945 10.1046/j.1460-9568.1998.00285.x (Pubitemid 28362576)
14. Calabresi P., Filippo M. D., Ghiglieri V., Tambasco N., Picconi B., Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. The Lancet Neurology 2010 9 11 1106 1117 2-s2.0-77957966489 10.1016/S1474-4422(10)70218-0
15. Filion M., Tremblay L., Bedard P. J., Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism. Brain Research 1991 547 1 152 161 2-s2.0-0025818631 10.1016/0006-8993(91)90586-K
16. Papa S. M., Desimone R., Fiorani M., Oldfield E. H., Internal globus pallidus discharge is nearly suppressed during levodopa-induced dyskinesias. Annals of Neurology 1999 46 5 732 738 2-s2.0-0032722841 10.1002/1531- 8249(199911)46:5732::AID-ANA8>3.0.CO;2-Q (Pubitemid 29518134)
17. Levy R., Dostrovsky J. O., Lang A. E., Sime E., Hutchison W. D., Lozano A. M., Effects of apomorphine on subthalamic nucleus and globus pallidus internus neurons in patients with Parkinson's disease. Journal of Neurophysiology 2001 86 1 249 260 2-s2.0-0034937264 (Pubitemid 32623230)
18. Lozano A. M., Lang A. E., Levy R., Hutchison W., Dostrovsky J., Neuronal recordings in Parkinson's disease patients with dyskinesias induced by apomorphine. Annals of Neurology 2000 47 4 supplement 1 S141 S146 2-s2.0-0034027547 (Pubitemid 30192019)
19. Merello M., Balej J., Delfino M., Cammarota A., Betti O., Leiguarda R., Apomorphine induces changes in GPi spontaneous outflow in patients with Parkinson's disease. Movement Disorders 1999 14 1 45 49 2-s2.0-0032929647 (Pubitemid 29224675)
20. Mitchell I. J., Boyce S., Sambrook M. A., Crossman A. R., A 2-deoxyglucose study of the effects of dopamine agonists on the Parkinsonian primate brain. Implications for the neural mechanisms that mediate dopamine agonist-induced dyskinesia. Brain 1992 115 809 824 2-s2.0-0026635584
21. Albin R. L., The pathophysiology of chorea/ballism and Parkinsonism. Parkinsonism and Related Disorders 1995 1 1 3 11 2-s2.0-0002475685
22. Albin R. L., Young A. B., Penney J. B., The functional anatomy of basal ganglia disorders. Trends in Neurosciences 1989 12 10 366 375 2-s2.0-0024450903 (Pubitemid 19238787)
23. Crossman A. R., Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience 1987 21 1 1 40 2-s2.0-0023268204 (Pubitemid 17076862)
24. DeLong M. R., Primate models of movement disorders of basal ganglia origin. Trends in Neurosciences 1990 13 7 281 285 2-s2.0-0025298139
25. Crossman A. R., Mitchell I. J., Sambrook M. A., Jackson A., Chorea and myoclonus in the monkey induced by gamma-aminobutyric acid antagonism in the lentiform complex. The site of drug action and a hypothesis for the neural mechanisms of chorea. Brain 1988 111 1211 1233 2-s2.0-0023736342
26. Hamada I., DeLong M. R., Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. Journal of Neurophysiology 1992 68 5 1850 1858 2-s2.0-0026498026
27. Mitchell I. J., Jackson A., Sambrook M. A., Crossman A. R., The role of the subthalamic nucleus in experimental chorea. Evidence from 2-deoxyglucose metabolic mapping and horseradish peroxidase tracing studies. Brain 1989 112 1533 1548 2-s2.0-0024851845 (Pubitemid 20024219)
28. 1 dopamine receptor. Journal of Neuroscience 2012 32 2 681 691 2-s2.0-84862908095 10.1523/JNEUROSCI.1541-11.2012
29. Iravani M. M., McCreary A. C., Jenner P., Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia. Parkinsonism and Related Disorders 2012 181 supplement 1 S123 S125
30. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology 2005 57 1 17 26 2-s2.0-19944427055 10.1002/ana.20296 (Pubitemid 40053311)
31. Bordet R., Ridray S., Schwartz J. C., Sokoloff P., Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. European Journal of Neuroscience 2000 12 6 2117 2123 2-s2.0-0034078964 10.1046/j.1460-9568.2000.00089.x (Pubitemid 30348849)
32. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B. H., Bloch B., Gurevich E. V., Gross C. E., Bezard E., Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. European Journal of Neuroscience 2005 22 1 283 287 2-s2.0-23044483789 10.1111/j.1460-9568.2005.04196.x (Pubitemid 41059995)
33. Picconi B., Centonze D., Håkansson K., Bernardi G., Greengard P., Fisone G., Cenci M. A., Calabresi P., Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neuroscience 2003 6 5 501 506 2-s2.0-0037407907 (Pubitemid 36514698)
34. 1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. Journal of Neuroscience 2009 29 15 4829 4835 2-s2.0-65549129089 10.1523/JNEUROSCI.5884-08.2009
35. 3 receptor function. Nature Medicine 2003 9 6 762 767 2-s2.0-0038579160 10.1038/nm875 (Pubitemid 36749227)
36. 3 receptor function and trafficking by heterodimerization. Molecular Pharmacology 2008 74 1 59 69 2-s2.0-45649085857 10.1124/mol.107.043885 (Pubitemid 351872159)
37. Smith Y., Raju D., Nanda B., Pare J. F., Galvan A., Wichmann T., The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Research Bulletin 2009 78 2-3 60 68 2-s2.0-58749101356 10.1016/j.brainresbull.2008.08.015
38. Villalba R. M., Smith Y., Neuroglial plasticity at striatal glutamatergic synapses in Parkinson's disease. Frontiers in Systems Neuroscience 2011 5, article 68
39. Gardoni F., Picconi B., Ghiglieri V., Polli F., Bagetta V., Bernardi G., Cattabeni F., Di Luca M., Calabresi P., A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia. Journal of Neuroscience 2006 26 11 2914 2922 2-s2.0-33644995350 10.1523/JNEUROSCI.5326-05.2006
40. Bateup H. S., Santini E., Shen W., Birnbaum S., Valjent E., Surmeier D. J., Fisone G., Nestler E. J., Greengard P., Distinct subclasses of medium spiny neurons differentially regulate striatal motor behaviors. Proceedings of the National Academy of Sciences of the United States of America 2010 107 33 14845 14850 2-s2.0-77957098636 10.1073/pnas.1009874107
41. Ghiglieri V., Picconi B., Calabresi P., Direct and indirect pathways in levodopa-induced dyskinesia: a more complex matter than a network imbalance. Movement Disorders 2010 25 11 1527 1529 2-s2.0-77955833738 10.1002/mds.23244
42. Belujon P., Lodge D. J., Grace A. A., Aberrant striatal plasticity is specifically associated with dyskinesia following levodopa treatment. Movement Disorders 2010 25 11 1568 1576 2-s2.0-77955828413 10.1002/mds.23245
43. Aron A. R., Obeso J., Is executive control used to compensate for involuntary movements in levodopa-induced dyskinesia? Movement Disorders 2012 27 3 339 340
44. Shoulson I., DATATOP: a decade of neuroprotective inquiry. Annals of Neurology 1998 44 3 supplement 1 S160 S166 2-s2.0-0031711714 (Pubitemid 28423844)
45. Rascol O., Brooks D. J., Korczyn A. D., Development of dyskinesias in a 5-year trial and ropinirole and L-dopa. Movement Disorders 2006 21 11 1844 1850 2-s2.0-33845188900 10.1002/mds.20988 (Pubitemid 44848929)
46. Hauser R. A., Rascol O., Korczyn A. D., Stoessl A. J., Watts R. L., Poewe W., De Deyn P. P., Lang A. E., Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders 2007 22 16 2409 2417 2-s2.0-38549168908 10.1002/mds.21743 (Pubitemid 351155989)
47. Watts R. L., Lyons K. E., Pahwa R., Sethi K., Stern M., Hauser R. A., Olanow W., Gray A. M., Adams B., Earl N. L., Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson's disease. Movement Disorders 2010 25 7 858 866 2-s2.0-77951941921 10.1002/mds.22890
48. Maratos E. C., Jackson M. J., Pearce R. K. B., Jenner P., Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus). Movement Disorders 2001 16 4 631 641 2-s2.0-0035412883 10.1002/mds.1149 (Pubitemid 36040842)
49. Holloway R., A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: design and methods of the CALM-PD study. Clinical Neuropharmacology 2000 23 1 34 44 2-s2.0-0033960907 10.1097/00002826-200001000-00007 (Pubitemid 30090410)
50. Holloway R., Marek K., Biglan K., Dick A., Fahn S., Julian-Baros E., Kamp C., Kieburtz K., Lang A., McDermott M., Seibyl J., Shinaman A., Shoulson I., Weiner W., Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Archives of Neurology 2009 66 5 563 570 2-s2.0-66249093789 10.1001/archneurol.2009.32
51. Bracco F., Battaglia A., Chouza C., Dupont E., Gershanik O., Masso J. F. M., Montastruc J. L., The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 2004 18 11 733 746 2-s2.0-4544226873 10.2165/00023210-200418110-00003 (Pubitemid 39243565)
52. Inzelberg R., Schechtman E., Nisipeanu P., Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. Drugs and Aging 2003 20 11 847 855 2-s2.0-0141649537 10.2165/00002512-200320110-00006 (Pubitemid 37159602)
53. Pinero A., Marcos-Alberca P., Fortes J., Cabergoline-related severe restrictive mitral regurgitation. The New England Journal of Medicine 2005 353 18 1976 1977 2-s2.0-27644505774 10.1056/NEJM200511033531822 (Pubitemid 41565968)
54. Voon V., Fernagut P. O., Wickens J., Baunez C., Rodriguez M., Pavon N., Juncos J. L., Obeso J. A., Bezard E., Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. The Lancet Neurology 2009 8 12 1140 1149 2-s2.0-72149094883 10.1016/S1474-4422(09)70287-X
55. Bélanger N., Grégoire L., Tahar A. H., Bédard P. J., Chronic treatment with small does of cabergoline prevents dopa-induced dyskinesias in Parkinsonian monkeys. Movement Disorders 2003 18 12 1436 1441 2-s2.0-0345770367 10.1002/mds.10589 (Pubitemid 38035365)
56. Pirtosek Z., Merello M., Carlsson A., Stern G., Preclamol and parkinsonian fluctuations. Clinical Neuropharmacology 1993 16 6 550 554 2-s2.0-0027332566
57. Lieberman J. A., Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004 18 4 251 267 2-s2.0-1642283136 10.2165/00023210-200418040-00005 (Pubitemid 38393435)
58. Meco G., Stirpe P., Edito F., Purcaro C., Valente M., Bernardi S., Vanacore N., Aripiprazole in l-dopa-induced dyskinesias: a one-year open-label pilot study. Journal of Neural Transmission 2009 116 7 881 884 2-s2.0-67651149481 10.1007/s00702-009-0231-z
59. Oh J. D., Bibbiani F., Chase T. N., Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Experimental Neurology 2002 177 2 557 564 2-s2.0-0036434679 10.1006/exnr.2002. 8009 (Pubitemid 35366144)
60. Katzenschlager R., Manson A. J., Evans A., Watt H., Lees A. J., Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study. Journal of Neurology, Neurosurgery and Psychiatry 2004 75 2 295 297 2-s2.0-0842309193 (Pubitemid 38183542)
61. Durif F., Debilly B., Galitzky M., Morand D., Viallet F., Borg M., Thobois S., Broussolle E., Rascol O., Clozapine improves dyskinesias in Parkinson disease A double-blind, placebo-controlled study. Neurology 2004 62 3 381 388 2-s2.0-1042299831 (Pubitemid 38200847)
62. Metman L. V., Del Dotto P., Blanchet P. J., Van Den Munckhof P., Chase T. N., Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids 1998 14 13 75 82 2-s2.0-0031975428 10.1007/BF01345246 (Pubitemid 28051155)
63. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L. V., Chase T. N., Bonuccelli U., Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Movement Disorders 2001 16 3 515 520 2-s2.0-0035353741 10.1002/mds.1112 (Pubitemid 36041158)
64. Luginger E., Wenning G. K., Bösch S., Poewe W., Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease. Movement Disorders 2000 15 5 873 878 2-s2.0-0034890953
65. Snow B. J., Macdonald L., Mcauley D., Wallis W., The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study. Clinical Neuropharmacology 2000 23 2 82 85 2-s2.0-0033999316 10.1097/00002826-200003000-00004 (Pubitemid 30212217)
66. Thomas A., Iacono D., Luciano A. L., Armellino K., Di Iorio A., Onofrj M., Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. Journal of Neurology, Neurosurgery and Psychiatry 2004 75 1 141 143 2-s2.0-0345863897 (Pubitemid 38091285)
67. Merello M., Perez-Lloret S., Antico J., Obeso J. A., Dyskinesias induced by subthalamotomy in Parkinson's disease are unresponsive to amantadine. Journal of Neurology, Neurosurgery and Psychiatry 2006 77 2 172 174 2-s2.0-32344431779 10.1136/jnnp.2005.068940 (Pubitemid 43220836)
68. Merello M., Nouzeilles M. I., Cammarota A., Leiguarda R., Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study. Clinical Neuropharmacology 1999 22 5 273 276 2-s2.0-0032730121 (Pubitemid 29506396)
69. Lökk J., Memantine can relieve certain symptoms in Parkinson's disease. Lakartidningen 2004 101 23 2003 2006 2-s2.0-3042567248 (Pubitemid 38886777)
70. Varanese S., Howard J., Di Rocco A., NMDA antagonist memantine improves levodopa-induced dyskinesias and on-off phenomena in Parkinson's disease. Movement Disorders 2010 25 4 508 510 2-s2.0-77949495194 10.1002/mds.22917
71. Braz C. A., Borges V., Ferraz H. B., Effect of riluzole on dyskinesia and duration of the on state in Parkinson disease patients: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology 2004 27 1 25 29 2-s2.0-1442300051 10.1097/00002826-200401000-00008 (Pubitemid 38280384)
72. Bara-Jimenez W., Dimitrova T. D., Sherzai A., Aksu M., Chase T. N., Glutamate release inhibition ineffective in levodopa-induced motor complications. Movement Disorders 2006 21 9 1380 1383 2-s2.0-33750345592 10.1002/mds.20976 (Pubitemid 44613289)
73. Durif F., Vidailhet M., Bonnet A. M., Blin J., Agid Y., Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995 45 10 1855 1858 2-s2.0-0029431964 (Pubitemid 27122957)
74. Kleedorfer B., Lees A. J., Stern G. M., Buspirone in the treatment of levodopa induced dyskinesias. Journal of Neurology Neurosurgery and Psychiatry 1991 54 4 376 377 2-s2.0-0025727854
75. Bonifati V., Fabrizio E., Cipriani R., Vanacore N., Meco G., Buspirone in levodopa-induced dyskinesias. Clinical Neuropharmacology 1994 17 1 73 82 2-s2.0-0028057911 (Pubitemid 24046709)
76. Meco G., Fabrizio E., Di Rezze S., Alessandri A., Pratesi L., Mirtazapine in L-dopa-induced dyskinesias. Clinical Neuropharmacology 2003 26 4 179 181 2-s2.0-0042134789 10.1097/00002826-200307000-00005 (Pubitemid 36951061)
77. Samadi P., Grégoire L., Bédard P. J., The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys. Neurobiology of Disease 2004 16 1 246 253 2-s2.0-2342576336 10.1016/j.nbd.2004.02.002 (Pubitemid 38569815)
78. Koprich J. B., Fox S. H., Johnston T. H., Goodman A., Le Bourdonnec B., Dolle R. E., Dehaven R. N., Dehaven-Hudkins D. L., Little P. J., Brotchie J. M., The selective mu-opioid receptor antagonist adl5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in mptp-lesioned macaque model of Parkinson's disease. Movement Disorders 2011 26 7 1225 1233 2-s2.0-79959365207 10.1002/mds.23631
79. Carroll C. B., Bain P. O., Teare L., Liu X., Joint C., Wroath C., Parkin S. G., Fox P., Wright D., Hobart J., Zajicek J. P., Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004 63 7 1245 1250 2-s2.0-20844441058 (Pubitemid 39350025)
80. Carpentier A. F., Bonnet A. M., Vidailhet M., Agid Y., Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease. Neurology 1996 46 6 1548 1551 2-s2.0-0029884740 (Pubitemid 26185769)
81. Buck K., Voehringer P., Ferger B., The α 2 adrenoceptor antagonist idazoxan alleviates l-DOPA-induced dyskinesia by reduction of striatal dopamine levels: an in vivo microdialysis study in 6-hydroxydopamine-lesioned rats. Journal of Neurochemistry 2010 112 2 444 452 2-s2.0-72849153132 10.1111/j.1471-4159.2009.06482.x
82. Grondin R., Tahar A. H., Doan V. D., Ladure P., Bédard P. J., Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schmiedeberg's Archives of Pharmacology 2000 361 2 181 186 2-s2.0-0033967659 10.1007/s002109900167 (Pubitemid 30062450)
83. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A. M., Descombes S., Bejjani B., Fabre N., Montastruc J. L., Agid Y., Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Movement Disorders 2001 16 4 708 713 2-s2.0-0035412888 10.1002/mds.1143 (Pubitemid 36040852)
84. Gottwald M. D., Aminoff M. J., Therapies for dopaminergic-induced dyskinesias in Parkinson disease. Annals of Neurology 2011 69 6 919 927 2-s2.0-79959480359 10.1002/ana.22423
85. Müller T., New small molecules for the treatment of Parkinson's disease. Expert Opinion on Investigational Drugs 2010 19 9 1077 1086 2-s2.0-77955604539 10.1517/13543784.2010.504711
86. Brooks D. J., Papapetropoulos S., Vandenhende F., Tomic D., He P., Coppell A., O'Neill G., An open-label, positron emission tomography study to assess adenosine A2A brain receptor occupancy of vipadenant (BIIB014) at steady-state levels in healthy male volunteers. Clinical Neuropharmacology 2010 33 2 55 60 2-s2.0-77951087570 10.1097/WNF.0b013e3181D137d2
87. Jankovic J., Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease? Annals of Neurology 2008 63 3 267 269 2-s2.0-41849115606 10.1002/ana.21348 (Pubitemid 351499855)
88. Pourcher E., Fernandez H. H., Stacy M., Mori A., Ballerini R., Chaikin P., Istradefylline for Parkinson's disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism and Related Disorders 2012 18 2 178 184 2-s2.0-84856216505 10.1016/j.parkreldis.2011.09.023
89. Fernandez H. H., Greeley D. R., Zweig R. M., Wojcieszek J., Mori A., Sussman N. M., Istradefylline as monotherapy for Parkinson disease: results of the 6002-US-051 trial. Parkinsonism and Related Disorders 2010 16 1 16 20 2-s2.0-74149087857 10.1016/j.parkreldis.2009.06.008
90. Hauser R. A., Shulman L. M., Trugman J. M., Roberts J. W., Mori A., Ballerini R., Sussman N. M., Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Movement Disorders 2008 23 15 2177 2185 2-s2.0-61449172156 10.1002/mds.22095
91. Stacy M., Silver D., Mendis T., Sutton J., Mori A., Chaikin P., Sussman N. M., A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology 2008 70 23 2233 2240 2-s2.0-44949229417 10.1212/01.wnl.0000313834.22171.17
92. LeWitt P. A., Guttman M., Tetrud J. W., Tuite P. J., Mori A., Chaikin P., Sussman N. M., Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Annals of Neurology 2008 63 3 295 302 2-s2.0-41849131038 10.1002/ana.21315 (Pubitemid 351499859)
93. Hauser R. A., Cantillon M., Pourcher E., Micheli F., Mok V., Onofrj M., Huyck S., Wolski K., Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial. The Lancet Neurology 2011 10 3 221 229 2-s2.0-79951720949 10.1016/S1474-4422(11)70012-6
94. Contin M., Martinelli P., Albani F., Scaglione C., Avoni P., Rizzo G., Baruzzi A., Kinetic-dynamic monitoring of levetiracetam effects in patients with Parkinson disease and levodopa-induced dyskinesias. Clinical Neuropharmacology 2007 30 2 122 124 2-s2.0-34147206880 10.1097/wnf.0b013e318033a6c7 (Pubitemid 46581206)
95. Lyons K. E., Pahwa R., Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clinical Neuropharmacology 2006 29 3 148 153 2-s2.0-33746405294 10.1097/01.WNF. 0000220814.48360.F4 (Pubitemid 44503893)
96. Wolz M., Löhle M., Strecker K., Schwanebeck U., Schneider C., Reichmann H., Grählert X., Schwarz J., Storch A., Levetiracetam for levodopa-induced dyskinesia in Parkinson's disease: a randomized, double-blind, placebo-controlled trial. Journal of Neural Transmission 2010 117 11 1279 1286 2-s2.0-78651241450 10.1007/s00702-010-0472-x
97. Wong K. K., Alty J. E., Goy A. G., Raghav S., Reutens D. C., Kempster P. A., A randomized, double-blind, placebo-controlled trial of levetiracetam for dyskinesia in Parkinson's disease. Movement Disorders 2011 26 8 1552 1555 2-s2.0-79960613147 10.1002/mds.23687
98. Zesiewicz T. A., Sullivan K. L., Maldonado J. L., Tatum W. O., Hauser R. A., Open-label pilot study of levetiracetam (Keppra) for the treatment of levodopa-induced dyskinesias in Parkinson's disease. Movement Disorders 2005 20 9 1205 1209 2-s2.0-23644462322 10.1002/mds.20563 (Pubitemid 41632212)
99. Bronzova J., Sampaio C., Hauser R. A., Lang A. E., Rascol O., Theeuwes A., van de Witte S. V., van Scharrenburg G., Bruegel Study Group, Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Movement Disorders 2010 25 6 738 746 2-s2.0-77955079797
100. Hauser R. A., Bronzova J., Sampaio C., Lang A. E., Rascol O., Theeuwes A., Van De Witte S. V., Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease for the pardoprunox study group. European Neurology 2009 62 1 40 48 2-s2.0-65449137170 10.1159/000216839
101. Rascol O., Bronzova J., Hauser R. A., Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism and Related Disorders 2012 18 4 370 376 2-s2.0-84860377625 10.1016/j.parkreldis. 2011.12.006
102. Stocchi F., Arnold G., Onofrj M., Kwiecinski H., Szczudlik A., Thomas A., Bonuccelli U., Van Dijk A., Cattaneo C., Sala P., Fariello R. G., Improvement of motor function in early Parkinson disease by safinamide. Neurology 2004 63 4 746 748 2-s2.0-4143093673 (Pubitemid 39100843)
103. Grosset D., Grosset A., The movement disorder society14th international congress of Parkinson's disease and movement disorders. IDrugs 2010 13 8 539 542 2-s2.0-77955368304
104. Berg D., Godau J., Trenkwalder C., Eggert K., Csoti I., Storch A., Huber H., Morelli-Canelo M., Stamelou M., Ries V., Wolz M., Schneider C., Di Paolo T., Gasparini F., Hariry S., Vandemeulebroecke M., Abi-Saab W., Cooke K., Johns D., Gomez-Mancilla B., AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Movement Disorders 2011 26 7 1243 1250 2-s2.0-79959372108 10.1002/mds.23616
105. Fregni F., Simon D. K., Wu A., Pascual-Leone A., Non-invasive brain stimulation for Parkinson's disease: a systematic review and meta-analysis of the literature. Journal of Neurology, Neurosurgery and Psychiatry 2005 76 12 1614 1623 2-s2.0-28144444507 10.1136/jnnp.2005.069849 (Pubitemid 41697622)
106. Chase T. N., Baronti F., Fabbrini G., Heuser I. J., Juncos J. L., Mouradian M. M., Rationale for continuous dopaminomimetic therapy of Parkinson's disease. Neurology 1989 39 11 supplement 2 7 19 2-s2.0-0024820634
107. Horowski R., Marsden C. D., Obeso J. A., Continuous dopaminergic stimulation: state of the art and outlook. Journal of Neural Transmission, Supplement 1988 27 249 252 2-s2.0-0023763943
108. Obeso J. A., Grandas F., Herrero M. T., Horowski R., The role of pulsatile versus continuous dopamine receptor stimulation for functional recovery in Parkinson's disease. European Journal of Neuroscience 1994 6 6 889 897 2-s2.0-0028337689 10.1111/j.1460-9568.1994.tb00584.x (Pubitemid 24185313)
109. Mouradian M. M., Heuser I. J. E., Baronti F., Chase T. N., Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Annals of Neurology 1990 27 1 18 23 2-s2.0-0025129116 10.1002/ana.410270105 (Pubitemid 20031354)
110. Antonini A., Isaias I. U., Canesi M., Zibetti M., Mancini F., Manfredi L., Dal Fante M., Lopiano L., Pezzoli G., Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome. Movement Disorders 2007 22 8 1145 1149 2-s2.0-34447545480 10.1002/mds.21500 (Pubitemid 47067225)
111. Devos D., Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Movement Disorders 2009 24 7 993 1000
112. Nyholm D., Lewander T., Johansson A., LeWitt P. A., Lundqvist C., Aquilonius S. M., Enteral levodopa/carbidopa infusion in advanced Parkinson disease: long-term exposure. Clinical Neuropharmacology 2008 31 2 63 73 2-s2.0-41749084435 10.1097/WNF.0b013e3180ed449f (Pubitemid 351489331)
113. Nyholm D., Nilsson Remahl A. I. M., Dizdar N., Constantinescu R., Holmberg B., Jansson R., Aquilonius S. M., Askmark H., Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005 64 2 216 223 2-s2.0-12544252127
114. Müller T., Renger K., Kuhn W., Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration. Archives of Neurology 2004 61 5 657 660 2-s2.0-2442623636 10.1001/archneur.61.5.657 (Pubitemid 38637680)
115. Onofrj M., Bonanni L., Cossu G., Manca D., Stocchi F., Thomas A., Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. Parkinsonism and Related Disorders 2009 15 supplement 3 S233 S236 2-s2.0-71849119462 10.1016/S1353-8020(09)70821-1
116. Block G., Liss C., Reines S., Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. European Neurology 1997 37 1 23 27 2-s2.0-8044229410 (Pubitemid 27037728)
117. Stocchi F., Rascol O., Kieburtz K., Poewe W., Jankovic J., Tolosa E., Barone P., Lang A. E., Olanow C. W., Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Annals of Neurology 2010 68 1 18 27 2-s2.0-77954043228 10.1002/ana.22060
118. Stoessl A. J., Continuous dopaminergic therapy in Parkinson disease: time to stride back? Annals of Neurology 2010 68 1 3 5 2-s2.0-77954039096 10.1002/ana.22079
119. Hauser R. A., Ellenbogen A. L., Metman L. V., Hsu A., O'Connell M. J., Modi N. B., Yao H. M., Kell S. H., Gupta S. K., Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Movement Disorders 2011 26 12 2246 2252 2-s2.0-79960145975 10.1002/mds.23861
120. Stocchi F., Ruggieri S., Vacca L., Olanow C. W., Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain 2002 125 2058 2066 2-s2.0-0036723589
121. Obeso J. A., Luquin M. R., Martinez-Lage J. M., Lisuride infusion pump: a device for the treatment of motor fluctuations in Parkinson's disease. The Lancet 1986 1 8479 467 470 2-s2.0-0022641131 (Pubitemid 16138332)
122. Vaamonde J., Luquin M. R., Obeso J. A., Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain 1991 114 601 617 2-s2.0-0025972525
123. Manson A. J., Turner K., Lees A. J., Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Movement Disorders 2002 17 6 1235 1241 2-s2.0-0036869028 10.1002/mds.10281 (Pubitemid 36041337)
124. García Ruiz P. J., Ignacio Á. S., Pensado B. A., Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Movement Disorders 2008 23 8 1130 1136 2-s2.0-52649108045 10.1002/mds.22063
125. Katzenschlager R., Hughes A., Evans A., Manson A. J., Hoffmann M., Swinn L., Watt H., Bhatia K., Quinn N., Lees A. J., Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Movement Disorders 2005 20 2 151 157 2-s2.0-20144366287 10.1002/mds.20276 (Pubitemid 40361117)
126. Ohye C., Maeda T., Narabayashi H., Physiologically defined VIM nucleus. Its special reference to control of tremor. Applied Neurophysiology 1976 39 3-4 285 295 2-s2.0-0017027027 (Pubitemid 8286631)
127. Lenz F. A., Kwan H. C., Martin R. L., Tasker R. R., Dostrovsky J. O., Lenz Y. E., Single unit analysis of the human ventral thalamic nuclear group. Tremor-related activity in functionally identified cells. Brain 1994 117 531 543 2-s2.0-0028364018
128. Tasker R. R., Kiss Z. H. T., The role of the thalamus in functional neurosurgery. Neurosurgery Clinics of North America 1995 6 1 73 104 2-s2.0-0028925040
129. Van Buren J. M., Li C. L., Shapiro D. Y., A qualitative and quantitative
130. Husby J., Korsgaard A. G., Proceedings: late results of thalamotomy in Parkinsonism with and without the influence of levodopa. Acta Neurochirurgica 1975 31 3-4 260 2-s2.0-0016625581
131. Derome P. J., Jedynak C. P., Visot A., Delalande O., Treatment of abnormal movements by thalamic lesions. Revista de Neurología 1986 142 4 391 397 (Pubitemid 16063429)
132. Nagaseki Y., Shibazaki T., Hirai T., Long-term follow-up results of selective VIM-thalamotomy. Journal of Neurosurgery 1986 65 3 296 302 2-s2.0-0022470521 (Pubitemid 16042434)
133. Fox M. W., Ahlskog J. E., Kelly P. J., Stereotactic ventrolateralis thalamotomy for medically refractory tremor in post-levodopa era Parkinson's disease patients. Journal of Neurosurgery 1991 75 5 723 730 2-s2.0-0025997101
134. Jankovic J., Cardoso F., Grossman R. G., Hamilton W. J., Tasker R. R., Kelly P. J., Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery 1995 37 4 680 687 2-s2.0-0029098945
135. Kelly P. J., Gillingham F. J., The long-term results of stereotaxic surgery and L-dopa therapy in patients with Parkinson's disease. A 10-year follow-up study. Journal of Neurosurgery 1980 53 3 332 327 2-s2.0-0018824981 (Pubitemid 10052151)
136. Miyamoto T., Bekku H., Moriyama E., Tsuchida S., Present role of stereotactic thalamotomy for Parkinsonism. Retrospective analysis of operative results and thalamic lesions in computed tomograms. Applied Neurophysiology 1985 48 16 294 304 2-s2.0-0022234811 (Pubitemid 16064613)
137. Diederich N., Goetz C. G., Stebbins G. T., Klawans H. L., Nittner K., Koulosakis A., Sanker P., Sturm V., Blinded evaluation confirms long-term asymmetric effect of unilateral thalamotomy or subthalamotomy on tremor in Parkinson's disease. Neurology 1992 42 7 1311 1314 2-s2.0-0026643613
138. Narabayashi H., Yokochi F., Nakajima Y., Levodopa-induced dyskinesia and thalamotomy. Journal of Neurology Neurosurgery and Psychiatry 1984 47 8 831 839 2-s2.0-0021134868 (Pubitemid 14059375)
139. Page R. D., Sambrook M. A., Crossman A. R., Thalamotomy for the alleviation of levodopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated Parkinsonian monkey. Neuroscience 1993 55 1 147 165 2-s2.0-0027286045 10.1016/0306-4522(93)90462-O (Pubitemid 23194993)
140. Benabid A. L., Pollak P., Hommel M., Gaio J. M., de Rougemont J., Perret J., Treatment of Parkinson tremor by chronic stimulation of the ventral intermediate nucleus of the thalamus. Revista de Neurología 1989 145 4 320 323 (Pubitemid 19106960)
141. Benabid A. L., Pollak P., Seigneuret E., Hoffmann D., Gay E., Perret J., Chronic VIM thalamic stimulation in Parkinson's disease, essential tremor and extra-pyramidal dyskinesias. Acta Neurochirurgica, Supplement 1993 58 39 44 2-s2.0-0027751037
142. Limousin P., Speelman J. D., Gielen F., Janssens M., Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. Journal of Neurology Neurosurgery and Psychiatry 1999 66 3 289 296 2-s2.0-0032954029 (Pubitemid 29103482)
143. Hariz M. I., Krack P., Alesch F., Augustinsson L. E., Bosch A., Ekberg R., Johansson F., Johnels B., Meyerson B. A., N'Guyen J. P., Pinter M., Pollak P., Von Raison F., Rehncrona S., Speelman J. D., Sydow O., Benabid A. L., Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. Journal of Neurology, Neurosurgery and Psychiatry 2008 79 6 694 699 2-s2.0-44449139009 10.1136/jnnp.2007.118653 (Pubitemid 351829444)
144. Tasker R. R., Munz M., Junn F. S., Kiss Z. H., Davis K., Dostrovsky J. O., Lozano A. M., Deep brain stimulation and thalamotomy for tremor compared. Acta Neurochirurgica. Supplement 1997 68 49 53 2-s2.0-0030634385
145. Blond S., Caparros-Lefebvre D., Parker F., Assaker R., Petit H., Guieu-J. D., Christiaens J. L., Control of tremor and involuntary movement disorders by chronic stereotactic stimulation of the ventral intermediate thalamic nucleus. Journal of Neurosurgery 1992 77 1 62 68 2-s2.0-0026764587
146. Caparros-Lefebvre D., Blond S., Vermersch P., Pecheux N., Guieu J. D., Petit H., Chronic thalamic stimulation improves tremor and levodopa induced dyskinesias in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1993 56 3 268 273 2-s2.0-0027516811 (Pubitemid 23101207)
147. Caparros-Lefebvre D., Blond S., Feltin M. P., Pollak P., Benabid A. L., Improvement of levodopa induced dyskinesias by thalamic deep brain stimulation is related to slight variation in electrode placement: possible involvement of the centre median and parafascicularis complex. Journal of Neurology Neurosurgery and Psychiatry 1999 67 3 308 314 2-s2.0-0032812869 (Pubitemid 29392589)
148. Lanciego J. L., Rodríguez-Oroz M. C., Blesa F. J., Alvarez-Erviti L., Guridi J., Barroso-Chinea P., Smith Y., Obeso J. A., Lesion of the centromedian thalamic nucleus in MPTP-treated monkeys. Movement Disorders 2008 23 5 708 715 2-s2.0-44449118898 10.1002/mds.21906
149. Laitinen L. V., Bergenheim A. T., Hariz M. I., Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease. Journal of Neurosurgery 1992 76 1 53 61 2-s2.0-0026536547
150. Hariz M. I., Bergenheim A. T., A 10-year follow-up review of patients who underwent Leksell's posteroventral pallidotomy for Parkinson disease. Journal of Neurosurgery 2001 94 4 552 558 2-s2.0-0034866921 (Pubitemid 32799647)
151. Baron M. S., Vitek J. L., Bakay R. A., Green J., McDonald W. M., Cole S. A., DeLong M. R., Treatment of advanced Parkinson's disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Movement Disorders 2000 15 2 230 237 (Pubitemid 30166728)
152. Obeso J. A., Olanow C. W., Rodriguez-Oroz M. C., Krack P., Kumar R., Lang A. E., Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. The New England Journal of Medicine 2001 345 13 956 963 2-s2.0-0035960120 10.1056/NEJMoa000827
153. Rodriguez-Oroz M. C., Obeso J. A., Lang A. E., Houeto J. L., Pollak P., Rehncrona S., Kulisevsky J., Albanese A., Volkmann J., Hariz M. I., Quinn N. P., Speelman J. D., Guridi J., Zamarbide I., Gironell A., Molet J., Pascual-Sedano B., Pidoux B., Bonnet A. M., Agid Y., Xie J., Benabid A. L., Lozano A. M., Saint-Cyr J., Romito L., Contarino M. F., Scerrati M., Fraix V., Van Blercom N., Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005 128 2240 2249 2-s2.0-26044468127 10.1093/brain/awh571 (Pubitemid 41407964)
154. Volkmann J., Allert N., Voges J., Sturm V., Schnitzler A., Freund H. J., Long-term results of bilateral pallidal stimulation in Parkinson's disease. Annals of Neurology 2004 55 6 871 875 2-s2.0-2542571133 10.1002/ana.20091 (Pubitemid 38702583)
155. Moro E., Lozano A. M., Pollak P., Agid Y., Rehncrona S., Volkmann J., Kulisevsky J., Obeso J. A., Albanese A., Hariz M. I., Quinn N. P., Speelman J. D., Benabid A. L., Fraix V., Mendes A., Welter M. L., Houeto J. L., Cornu P., Dormont D., Tornqvist A. L., Ekberg R., Schnitzler A., Timmermann L., Wojtecki L., Gironell A., Rodriguez-Oroz M. C., Guridi J., Bentivoglio A. R., Contarino M. F., Romito L., Scerrati M., Janssens M., Lang A. E., Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Movement Disorders 2010 25 5 578 586 2-s2.0-77951234550 10.1002/mds.22735
156. Alvarez L., Macias R., Pavón N., López G., Rodríguez-Oroz M. C., Rodríguez R., Alvarez M., Pedroso I., Teijeiro J., Fernández R., Casabona E., Salazar S., Maragoto C., Carballo M., García I., Guridi J., Juncos J. L., DeLong M. R., Obeso J. A., Therapeutic efficacy of unilateral subthalamotomy in Parkinson's disease: results in 89 patients followed for up to 36 months. Journal of Neurology, Neurosurgery and Psychiatry 2009 80 9 979 985 2-s2.0-69449095866 10.1136/jnnp.2008.154948
157. Krack P., Pollak P., Limousin P., Benazzouz A., Deuschl G., Benabid A. L., From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999 122 1133 1146 2-s2.0-0032692741 10.1093/brain/122.6.1133 (Pubitemid 29533128)
158. Stolze H., Klebe S., Poepping M., Lorenz D., Herzog J., Hamel W., Schrader B., Raethjen J., Wenzelburger R., Mehdorn H. M., Deuschl G., Krack P., Effects of bilateral subthalamic nucleus stimulation on parkinsonian gait. Neurology 2001 57 1 144 146 2-s2.0-0035838409 (Pubitemid 32634868)
159. Simuni T., Jaggi J. L., Mulholland H., Hurtig H. I., Colcher A., Siderowf A. D., Ravina B., Skolnick B. E., Goldstein R., Stern M. B., Baltuch G. H., Bilateral stimulation of the subthalamic nucleus in patients with Parkinson disease: a study of efficacy and safety. Journal of Neurosurgery 2002 96 4 666 672 2-s2.0-0036130274 (Pubitemid 34245620)
160. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., Koudsie A., Limousin P. D., Benazzouz A., LeBas J. F., Benabid A. L., Pollak P., Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. The New England Journal of Medicine 2003 349 20 1925 1934 2-s2.0-0242658923 10.1056/NEJMoa035275 (Pubitemid 37409709)
161. Rodriguez-Oroz M. C., Zamerbide I., Gyridi J., Palmero M. R., Obeso J. A., Efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease 4 years after surgery: double blind and label evaluation. Journal of Neurology, Neurosurgery and Psychiatry 2004 75 10 1382 1385 2-s2.0-4644228624 10.1136/jnnp.2003.031294 (Pubitemid 39279802)
162. Deuschl G., Schade-Brittinger C., Krack P., A randomized trial of deep-brain stimulation for Parkinson's disease. The New England Journal of Medicine 2006 355 9 896 908 (Pubitemid 44315982)
163. Hamani C., Richter E., Schwalb J. M., Lozano A. M., Bilateral subthalamic nucleus stimulation for Parkinson's disease: a systematic review of the clinical literature. Neurosurgery 2005 56 6 1313 1324 2-s2.0-20044394929 10.1227/01.NEU.0000159714.28232.C4 (Pubitemid 40770456)
164. Follett K. A., Comparison of pallidal and subthalamic deep brain stimulation for the treatment of levodopa-induced dyskinesias. Neurosurg Focus 2004 17 1 E3 2-s2.0-5444260785
165. Limousin P., Krack P., Pollak P., Benazzouz A., Ardouin C., Hoffmann D., Benabid A. L., Electrical stimulation of the subthalamic nucleus in advanced Parkinsonian's disease. The New England Journal of Medicine 1998 339 16 1105 1111 2-s2.0-0032531683 10.1056/NEJM199810153391603 (Pubitemid 28465758)
166. Montgomery E. B., Baker K. B., Mechanisms of deep brain stimulation and future technical developments. Neurological Research 2000 22 3 259 266 2-s2.0-0342804260 (Pubitemid 30230154)
167. Vingerhoets F. J. G., Villemure J. G., Temperli P., Pollo C., Pralong E., Ghika J., Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. Neurology 2002 58 3 396 401 2-s2.0-0037065791 (Pubitemid 34150913)
168. Russmann H., Ghika J., Villemure J. G., Robert B., Bogousslavsky J., Burkhard P. R., Vingerhoets F. J. G., Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology 2004 63 10 1952 1954 2-s2.0-8844270229 (Pubitemid 39532401)
169. Molinuevo J. L., Valldeoriola F., Tolosa E., Rumiá J., Valls-Solé J., Roldan H., Ferrer E., Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. Archives of Neurology 2000 57 7 983 988 2-s2.0-0033936304 (Pubitemid 30452503)
170. Figueiras-Mendez R., Marin-Zarza F., Molina J. A., Jimenez-Jimenez F. J., Orti-Pareja M., Magarinos C., Lopez-Pino M. A., Martinez V., Subthalamic nucleus stimulation improves directly levodopa induced dyskinesias in Parkinson's disease. Journal of Neurology Neurosurgery and Psychiatry 1999 66 4 549 550 2-s2.0-0032970043 (Pubitemid 29145702)
171. Rodriguez-Oroz M. C., Gorospe A., Guridi J., Ramos E., Linazasoro G., Rodriguez-Palmero M., Obeso J. A., Bilateral deep brain stimulation of the subthalamic nucleus in Parkinson's disease. Neurology 2000 55 12 supplement 6 S45 S51 2-s2.0-0034719049 (Pubitemid 32103943)
172. Obeso J. A., Rodriguez-Oroz M., Marin C., The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 2004 62 1 supplement 1 S17 S30 2-s2.0-9144249598 (Pubitemid 38082849)
173. Saint-Cyr J. A., Hoque T., Pereira L. C. M., Dostrovsky J. O., Hutchison W. D., Mikulis D. J., Abosch A., Sime E., Lang A. E., Lozano A. M., Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. Journal of Neurosurgery 2002 97 5 1152 1166 2-s2.0-0036829595 (Pubitemid 35253553)
174. Voges J., Volkmann J., Allert N., Lehrke R., Koulousakis A., Freund H. J., Sturm V., Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. Journal of Neurosurgery 2002 96 2 269 279 2-s2.0-0036120075 (Pubitemid 34230241)
175. Hamel W., Fietzek U., Morsnowski A., Schrader B., Herzog J., Weinert D., Pfister G., Müller D., Volkmann J., Deuschl G., Mehdorn H. M., Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: evaluation of active electrode contacts. Journal of Neurology Neurosurgery and Psychiatry 2003 74 8 1036 1046 2-s2.0-0042706300 10.1136/jnnp.74.8.1036 (Pubitemid 36936377)
176. Guridi J., Obeso J. A., Rodriguez-Oroz M. C., Lozano A. A., Manrique M., L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease. Neurosurgery 2008 62 2 311 323 2-s2.0-41749125649 10.1227/01.neu.0000315998. 58022.55